Reset filter
Mots-clés
Treatment Form ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
    1. 1.1. Inclusion/exclusion
    1. 1.2. Anamnèse
    1. 1.3. Examen médical
    1. 1.4. Score
    1. 1.5. Diagnostic à l’aide d’appareils
    1. 1.6. Laboratoire
    1. 1.7. Pathologie/histologie
    1. 1.8. Informations/consentement
    1. 1.9. Thérapie
    1. 1.10. Rapport opératoire
    1. 1.11. Évènement inopportun
    1. 1.12. Follow-Up
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

679 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Breast Cancer NCT00433589 Treatment - Endocrine therapy - 2498727v1.0 - Endocrine therapy

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Header, Endocrine therapy, Footer Module
Endocrine therapy Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19677A9A-FFBD-2E6F-E044-0003BA3F9857

Infection Episode

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 11 Eléments de données, 1 Langue
Groupe Item: Infection Episode
Information summarizing episodes of infection associated with treatment. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=ACFF6F4C-B15B-1776-E040-BB89AD43285B

Treatment - Study Medication Administration - 3280117v1.0 - Study Medication Administration

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 16 Eléments de données, 1 Langue
Groupe Item: Study Medication Administration
Record study medication administration. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AD24494B-49FC-235C-E040-BB89AD4305F5

Effect of casoptiant on cardiac conduction as compared to placebo and moxifloxacin 103447 - Randomisation Number; Investigational Product; Treatment Confirmation

- 17/06/2020 - 1 Formulaire, 4 Groupes Item, 7 Eléments de données, 1 Langue
Groupes Item: Administrative, Randomisation Number, Investigational Product, Treatment Confirmation
Study ID: 103447 Clinical Study ID: NKV103447 Study Title:A study to evaluate the effect of casoptiant on cardiac conduction as assessed by 12-lead electrocardiogram as compared to placebo and moxifloxacin Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Screening - Prior Ovarian Cancer Treatment; Laboratory Tests; Lesion Assessment Record

- 23/08/2019 - 1 Formulaire, 13 Groupes Item, 48 Eléments de données, 1 Langue
Groupes Item: Administrative, Prior Ovarian Cancer Treatment - Chemotherapy, Has the patient received radiotherapy?, Prior Ovarian Cancer Treatment - Radiotherapy , Has the patient received prior cancer-related surgery?, Prior Ovarian Cancer Treatment - Surgical Treatment , Has the patient received other cancer-related treatments?, Other Cancer Related Treatments, Laboratory Tests (within 7 days prior to Day 1) - Haematology, Laboratory Tests (within 7 days prior to Day 1) - Haematology , Laboratory Tests (within 7 days prior to Day 1) - Chemistry, Laboratory Tests (within 7 days prior to Day 1) - Chemistry , Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Study Medication Administration

- 09/10/2017 - 1 Formulaire, 3 Groupes Item, 23 Eléments de données, 1 Langue
Groupes Item: Study Medication Administration, Study Drug Missed, Comments
Study Drug form for C3D 3.12 Adopter Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF055E17-C215-4937-E034-0003BA3F9857

Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825 Phase III GBM Salvage Treatment Guideline Questionnaire (SX) - 2797409v1.0 - RTOG 0825 Phase III GBM Salvage Treatment Guideline Questionnaire (SX)

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Header Module, Inclusion Criteria, Footer Module
RTOG 0825 Phase III GBM Salvage Treatment Guideline Questionnaire (SX) Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5AE28686-9246-64D7-E044-0003BA3F9857

Treatment - Breast Cancer - Adjuvant Radiotherapy Report Form - 2280049v3.0 - Breast Cancer - Adjuvant Radiotherapy Report Form

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: CRF Header, Breast: Form Administration, Breast: Radiation Treatment
Breast Cancer - Adjuvant Radiotherapy Report Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA18A97F-D17C-0637-E034-0003BA12F5E7

Induction Treatment Form Multiple Myeloma (E1A06)

- 01/01/2015 - 1 Formulaire, 10 Groupes Item, 78 Eléments de données, 1 Langue
Groupes Item: Header section, Vital Status, Patient Characteristics, Therapy Administered - Melphalan, Therapy Administered - Prednisone, Therapy Administered - Thalidomide, Therapy Administered - Prophylaxis Treatment, Therapy Administered - Lenalidomide, Non-Protocol Therapy, Comments
E1A06 Induction Treatment Form Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma NCT00602641 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=402A1AE1-FA70-56B0-E044-0003BA3F9857

Esophageal Cancer NCT00655876 Treatment - TF: Radiation Therapy Oncology Group Phase III Esophagus Systemic Treatment Summary Form - 2598533v1.0 - TF: Radiation Therapy Oncology Group Phase III Esophagus Systemic Treatment Summary Form

- 27/09/2021 - 1 Formulaire, 6 Groupes Item, 56 Eléments de données, 1 Langue
Groupes Item: MODULE 1, Summary of Systemic Treatment, Summary of Systemic Treatment, Protocol Specific Adverse Events Evaluation, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS, Footer
TF: Radiation Therapy Oncology Group Phase III Esophagus Systemic Treatment Summary Form Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=2A02FE34-6EF5-5B5C-E044-0003BA3F9857

Treatment - Infection Episode - 3277947v1.0 - Infection Episode

- 27/09/2021 - 1 Formulaire, 1 Groupe Item, 11 Eléments de données, 1 Langue
Groupe Item: Infection Episode
Information summarizing episodes of infection associated with treatment. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=ACFF6F4C-B15B-1776-E040-BB89AD43285B

Treatment Summary NSCLC Stage III RTOG NCT00533949

- 20/09/2021 - 1 Formulaire, 3 Groupes Item, 36 Eléments de données, 1 Langue
Groupes Item: RTOG clinical trial administrative data, Assessment of Chemotherapy, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS
NCT00533949 TF: Radiation Therapy Oncology Group Phase III High-dose Vs Standard-dose Conformal XRT with Chemotherapy Treatment Summary Form High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=24FB4F78-9A8F-669C-E044-0003BA3F9857

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial